Medication info

Janusitin 50 mg (Sitagliptin Hydrochloride Hydrate)

Prescription medicationTabletOralExpired
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tablet
Manufacturer / importer
Korea Pavis Pharmaceutical Co., Ltd.
Appearance
A light orange, round, biconvex, film-coated tablet
Packaging
28 tablets/box [14 tablets/PTP*2], 30 tablets/box [10 tablets/PTP*3]
Approval status
Expired

MFDS item code 202004056 · Approved 2020.05.29

This product's status changed to Expired on 2025.05.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine is administered at 100mg once daily, either as monotherapy or in combination therapy, with a maximum daily dose of 100mg. It may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Because dosage adjustment is required according to renal function, assessment of renal function before treatment with this medicine and periodically thereafter is recommended. No dosage adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR]≥60mL/min/1.73m2 and < 90mL/min/1.73m2). No dosage adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR]≥45mL/min/1.73m2 and < 60mL/min/1.73m2). In patients with moderate renal impairment (estimated glomerular filtration rate [eGFR]≥30mL/min/1.73m2 and < 45mL/min/1.73m2), administer 50mg once daily. In patients with severe renal impairment (estimated glomerular filtration rate [eGFR]≥15mL/min/1.73m2 and < 30mL/min/1.73m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR]< 15mL/min/1.73m2), administer 25mg once daily. This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Korea Pavis Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

  • Difficulty in blood sugar control for patients with type 2 diabetes
View approved original text

This medicine is used in conjunction with dietary control and exercise to help control blood sugar levels in patients with type 2 diabetes. It may be combined with metformin for those starting treatment for diabetes or if blood sugar control is difficult with monotherapy. Additionally, it can be added when blood sugar control is insufficient with either sulfonylureas, metformin, thiazolidinediones, or insulin monotherapy or combination therapy. This medicine helps to effectively improve blood sugar control by being used as an adjunctive treatment in various therapeutic approaches. Therefore, this medicine is used to enhance blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

This medicine is administered at 100mg once daily, either as monotherapy or in combination therapy, with a maximum daily dose of 100mg. It may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Because dosage adjustment is required according to renal function, assessment of renal function before treatment with this medicine and periodically thereafter is recommended. No dosage adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR]≥60mL/min/1.73m2 and < 90mL/min/1.73m2). No dosage adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR]≥45mL/min/1.73m2 and < 60mL/min/1.73m2). In patients with moderate renal impairment (estimated glomerular filtration rate [eGFR]≥30mL/min/1.73m2 and < 45mL/min/1.73m2), administer 50mg once daily. In patients with severe renal impairment (estimated glomerular filtration rate [eGFR]≥15mL/min/1.73m2 and < 30mL/min/1.73m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR]< 15mL/min/1.73m2), administer 25mg once daily. This medicine may be administered regardless of the timing of dialysis.

Precautions

This medicine may cause severe allergic reactions; therefore, if symptoms such as skin rash or difficulty breathing occur within 3 months of administration, immediately discontinue use and consult a doctor. This medicine may induce acute pancreatitis, so if symptoms such as abdominal pain, vomiting, or nausea appear, discontinue use immediately and inform healthcare professionals. This medicine should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and should also be avoided in those with allergies to the drug or its components. Patients with impaired kidney function may have difficulty excreting this medicine, thus dosage adjustment is necessary, and periodic kidney function tests are recommended. During treatment with this medicine, symptoms of hypoglycemia may occur; therefore, blood sugar levels should be monitored closely, especially when taken with insulin or sulfonylureas. If severe joint pain or skin blistering occurs, inform a doctor immediately and discontinue use. Pregnant or breastfeeding women are advised not to use this medicine, and its safety and efficacy have not been established in children or adolescents under 18 years of age. Elderly patients may experience decreased kidney function, so dosage adjustment and monitoring of kidney function is necessary. In the case of overdose, seek medical attention immediately for appropriate treatment, and consider that some may be removed by hemodialysis, thus it might be necessary to take this into account for dialysis patients. This medicine generally has low interaction with other diabetes medications, but when used in conjunction with specific drugs, blood concentrations may change, therefore, consultation with a doctor prior to use is necessary.

Side effects

Severe hypersensitivity reaction, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, hypoglycemia, upper respiratory tract infection, nasopharyngitis, headache, diarrhea, abdominal pain, nausea, constipation, vomiting, severe joint pain accompanied by disability, bullous pemphigoid-like eruption, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, pneumonia, diabetes complications, metabolic acidosis, falls, cardiac arrest, indigestion, dizziness, increased blood triglycerides, gastritis, weight loss, hypertension, hypernatremia, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a tightly sealed container to prevent air exposure, at room temperature between 1 degree and 30 degrees Celsius. Storing it this way will help maintain its effectiveness for a longer period.

Appearance and packaging

Appearance

A light orange, round, biconvex, film-coated tablet

Package unit

28 tablets/box [14 tablets/PTP*2], 30 tablets/box [10 tablets/PTP*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.